文献速递临床试验与 GCP

低剂量高频卡培他滨维持治疗对早期三阴性乳腺癌无病生存的影响:SYSUCC-001随机临床试验

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该随机临床试验纳入443例完成标准辅助化疗的早期三阴性乳腺癌患者,1:1分组接受卡培他滨650 mg/m²每日两次口服1年或观察。

要点

  • 低剂量卡培他滨维持治疗1年可显著改善早期三阴性乳腺癌5年无病生存率。
  • 最常见不良事件为手足综合征(45.2%),3级事件占7.7%。

核心结论

  • 在完成标准辅助治疗的早期三阴性乳腺癌女性中,低剂量卡培他滨维持治疗1年较观察显著改善5年无病生存。

研究设计与样本

  • 随机临床试验在中国13个学术中心及临床站点开展,2010年4月至2016年12月入组,最终随访日期2020年4月30日。
  • 443例完成标准辅助化疗的早期三阴性乳腺癌患者随机1:1分组,卡培他滨组222例,观察组221例;全分析集434例,98.0%完成试验。
  • 卡培他滨给药方案为650 mg/m²每日两次口服,持续1年不间断。

主要发现

  • 中位随访61个月(四分位距44-82),共观察94例事件;卡培他滨组38例事件(37例复发、32例死亡),观察组56例事件(56例复发、40例死亡)。
  • 最常见卡培他滨相关不良事件为手足综合征(45.2%),3级事件占7.7%。

临床怎么用

  • 对于完成标准辅助化疗的早期三阴性乳腺癌患者,可考虑低剂量卡培他滨维持治疗1年以改善无病生存。
  • 治疗期间需重点监测手足综合征等不良事件,3级手足综合征发生率为7.7%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed. OBJECTIVE: To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy. INTERVENTIONS: Eligible patients were randomized 1:1 to receive capecitabine (n = 222) at a dose of 650 mg/m2 twice a day by mouth for 1 year without interruption or to observation (n = 221) after completion of standard adjuvant chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival. Secondary end points included distant disease-free survival, overall survival, locoregional recurrence-free survival, and adverse events. RESULTS: Among 443 women who were randomized, 434 were included in the full analysis set (mean [SD] age, 46 [9.9] years; T1/T2 stage, 93.1%; node-negative, 61.8%) (98.0% completed the trial). After a median follow-up of 61 months (interquartile range, 44-82), 94 events were observed, including 38 events (37 recurrences and 32 deaths) in the capecitabine group and 56 events (56 recurrences and 40 deaths) in the observation group. The estimated 5-year disease-free survival was 82.8% in the capecitabine group and 73.0% in the observation group (hazard ratio [HR] for risk of recurrence or death, 0.64 [95% CI, 0.42-0.95]; P = .03). In the capecitabine group vs the observation group, the estimated 5-year distant disease-free survival was 85.8% vs 75.8% (HR for risk of distant metastasis or death, 0.60 [95% CI, 0.38-0.92]; P = .02), the estimated 5-year overall survival was 85.5% vs 81.3% (HR for risk of death, 0.75 [95% CI, 0.47-1.19]; P = .22), and the estimated 5-year locoregional recurrence-free survival was 85.0% vs 80.8% (HR for risk of locoregional recurrence or death, 0.72 [95% CI, 0.46-1.13]; P = .15). The most common capecitabine-related adverse event was hand-foot syndrome (45.2%), with 7.7% of patients experiencing a grade 3 event. CONCLUSIONS AND RELEVANCE: Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly improved 5-year disease-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01112826.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Wang X, Wang SS, Huang H, et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021. PMID: 33300950. doi:10.1001/jama.2020.23370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。